Shen Zhen Shang Bao·2025-10-29 10:18Core Viewpoint - Weikang Pharmaceutical reported a significant decline in revenue and net profit for the first three quarters of 2025, attributing the drop primarily to a reduction in the scope of consolidation [1][2]. Financial Performance - The company achieved a revenue of 151.32 million yuan, a year-on-year decrease of 59.2% [2]. - The net profit attributable to shareholders was -123.85 million yuan, reflecting a staggering year-on-year decline of 380.87% [1][2]. - The basic and diluted earnings per share were both -0.8554 yuan, down 380.83% compared to the previous year [2]. - The weighted average return on net assets was -11.40%, a decrease of 14.64% year-on-year [2]. Operational Insights - Weikang Pharmaceutical has faced consecutive losses in 2023 and 2024, with losses of 8.95 million yuan and 147 million yuan, respectively [2]. - The company is a national high-tech enterprise engaged in pharmaceutical research, production, and sales [3]. Project Delays - The "Marketing Network Center Construction Project" has experienced multiple delays, with the completion date extended from June 30, 2025, to June 30, 2026 [4][5]. - The cumulative investment in this project as of June 30, 2025, was 8.93 million yuan, with an investment progress of 41.68% [5]. Market Performance - As of October 29, the stock price of Weikang Pharmaceutical was 23.47 yuan per share, with a total market capitalization of 3.398 billion yuan [6]. - The stock has seen a price increase of 57.20% since the beginning of 2025 [6].